Showing results (101-110 of 115) with videos related to
Sort By:
Pageof 12
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.Plos One|July 30, 2014
Anti-HDV IgM as a marker of disease activity in hepatitis deltaAnika Wranke, Benjamin Heidrich, Stefanie Ernst, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2017
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)Anika Wranke, Lourdes M Pinheiro Borzacov, Raymundo Parana, et al.JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 3, 2023
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis DOlympia E Anastasiou, Florin A Caruntu, Manuela G Curescu, et al.Journal of Hepatology|February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationGeorge V Papatheodoridis, Vana Sypsa, George Dalekos, et al.Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.Journal of Hepatology|January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.The Lancet. Infectious Diseases|March 6, 2019
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trialHeiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, et al.Pageof 12